Urologix, Inc. (ULGX)

Urologix, Inc. (ULGX) — VMCI valuation read

ULGX prints VMCI 38/100 inside the Healthcare sector, where the median sits at 50. The 12-point below-median delta is the cleanest single-number summary of Urologix, Inc.'s composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.

On ULGX, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** ULGX trades at 16.0x earnings, 11% below the Healthcare median of 18.0x; that is the value line. ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of -1.8x leaves covenant headroom; that is the risk line for Urologix, Inc. on the trailing financials.

ULGX fell 2.4% over the trailing 7 days, with a -22.0% read on a 30-day basis.